Periostin: a novel prognostic predictor for meningiomas

Area of Science:

• Neuro-oncology
• Cancer Biology
• Pathology

Background:

• The role and expression of periostin in meningiomas are currently unknown.
• Meningiomas are primary tumors of the brain and spinal cord, with varying grades and prognoses.

Purpose of the Study:

• To investigate the expression of periostin and Ki67 in meningiomas.
• To determine the correlation of periostin and Ki67 expression with meningioma WHO grade.
• To analyze the prognostic value of periostin and Ki67 in meningioma patients.

Main Methods:

• Immunohistochemical analysis of 175 convexity meningioma tissue specimens using antibodies against periostin and Ki67.
• Comparison of periostin and Ki67 expression levels across different World Health Organization (WHO) grades.
• Statistical analysis to assess correlations between protein expression, tumor grade, brain invasion, and patient outcomes (recurrence, progression-free survival, overall survival).

Main Results:

• Ki67 expression significantly differed among WHO groups and correlated positively with WHO grade.
• Periostin expression also differed significantly among WHO groups and correlated positively with WHO grade.
• Positive correlations were found between Ki67 and periostin expression, and both were significantly different in cases with brain invasion.
• Both Ki67 and periostin expression levels were statistically different between groups with varying recurrence rates, progression-free survival (PFS), and survival times.

Conclusions:

• Periostin is expressed in the tumor stroma of meningiomas.
• Both periostin and Ki67 can serve as markers for predicting meningioma grade and prognosis.
• Further research into periostin-targeting drugs is warranted to reduce invasion in meningioma patients.